Johnson & Johnson announced today that new clinical and real-world data will be presented via 18 abstracts at the ASCO GU symposium being held January 25-27 in San Francisco, underlining the company's 'commitment to transforming the science of genitourinary (GU) cancers'.

In particular, the company will present new evidence for Erleada (apalutamide) in the treatment of various stages of prostate cancer, as well as data on the results of a Phase III study of niraparib plus abiraterone acetate administered with prednisone, and updates on the TAR-200 and TAR-210 targeted delivery systems.

Our data underscore the breadth and depth of J&J's GU portfolio, as well as our commitment to redefining treatment paradigms and launching new therapeutic advances for prostate and bladder cancer patients," said Luca Dezzani, Vice President of Medical Affairs and Solid Tumors at Johnson & Johnson Innovative Medicine.


Copyright (c) 2024 CercleFinance.com. All rights reserved.